ABT vs BSX vs RMD Stock Comparison

Abbott Laboratories, Boston Scientific and Resmed Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$187.09B
P/E
39.8x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
3 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$63.31B
P/E
18.1x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
3 wins
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.24B
P/E
21.5x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
5 wins

Head to Head

11 decided of 12

Resmed leads on 5 of the 12 questions below (Resmed 5, Abbott Laboratories 3, Boston Scientific 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTBSXRMDLeader
Larger companyMarket capitalisation $187.09B $63.31B $34.24B ABT
Cheaper on earningsLower P/E, profitable companies only 39.8x 18.1x 21.5x BSX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 14.5x 18.5x BSX
Faster revenue growthRevenue growth, trailing twelve months +10.0% +8.9% +9.0% ABT
More profitableNet margin, trailing twelve months 9.7% 16.6% 27.8% RMD
Better return on capitalReturn on invested capital 5.7% 9.9% 22.0% RMD
Less leveragedLower net debt / EBITDA 2.5x 2.1x -0.3x RMD
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -16.0% -57.8% -5.0% RMD
Better 5-year returnAnnualised price return, 5 years -3.3%/yr +1.1%/yr -1.2%/yr BSX
Less volatileAnnualised volatility, 1 year 28.5% 41.5% 31.1% ABT
Higher overall scoreMean of the five percentile scores vs peers 56/100 68/100 80/100 RMD

Percentile Scorecard

ABTBSXRMD

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTBSXRMD
Valuation 74 #65 of 243 87 #33 of 243 75 #62 of 243
Growth 26 #168 of 228 68 #73 of 228 60 #92 of 228
Profitability 82 #41 of 222 91 #20 of 222 99 #3 of 222
Financial Health 33 #167 of 248 43 #142 of 248 76 #61 of 248
Shareholder Returns 65 #56 of 158 48 #82 of 158 89 #18 of 158
Overall 56 68 80
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics
  • RMD ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTBSXRMDSPY
1 month +5.4%+3.1%+1.7% -2.0%
3 months -2.4%-14.5%+6.7% -2.8%
6 months +28.5%-15.8%+18.6% +2.0%
Year to date -13.4%-53.5%-0.6% +10.6%
1 year -16.0%-57.8%-5.0% +12.2%
3 years +11.8%-17.9%+62.6% +68.1%
3 years, per year +3.8%-6.4%+17.6% +18.9%
5 years -15.5%+5.4%-6.0% +61.4%
5 years, per year -3.3%+1.1%-1.2% +10.1%
10 years +170.4%+106.2%+300.2% +248.5%
10 years, per year +10.5%+7.5%+14.9% +13.3%

Risk

MeasureABTBSXRMDSPY
Volatility, 1Y 28.5%41.5%31.1% 13.6%
Downside volatility, 1Y 27.8%47.7%33.9% 13.9%
Beta vs S&P 500, 1Y 0.070.260.51 1.00
Return / volatility, 1Y -0.56-1.39-0.16 0.90
Max drawdown, 5Y -41.6%-61.6%-49.8% -25.4%
From 52-week high -16.9%-57.8%-13.2% -3.2%
52-week high $130.59$104.98$275.96 $779.14
52-week low $82.56$41.57$182.82 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTBSXRMD
P/E now vs peer median 40.0xmedian 26.5x 18.3xmedian 26.5x 21.5xmedian 26.5x
P/S now vs peer median 3.9xmedian 2.7x 3.1xmedian 2.7x 5.9xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 14.1xmedian 18.4x 15.8xmedian 18.4x
P/FCF now vs peer median 27.8xmedian 25.4x 19.3xmedian 25.4x 20.9xmedian 25.4x
P/B now vs peer median 3.6xmedian 2.5x 2.5xmedian 2.5x 5.7xmedian 2.5x
PEG now vs peer median -13.92median 0.98 0.42median 0.98 0.99median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTBSXRMD
Revenue $48.23B $21.07B $5.73B
Gross profit $27.46B $14.57B $3.50B
Operating income $6.65B $3.93B $1.89B
Net income $4.70B $3.49B $1.59B
Free cash flow $6.76B $3.33B $1.61B
R&D $3.31B $2.16B $393.82M
EPS (diluted) $2.70 $2.41 $11.11
Cash & equivalents $4.05B $609.00M $1.01B
Total debt $31.16B $11.95B $409.60M
Shares (diluted) 1.74B 1.45B 143.41M
Enterprise value $160.95B $58.74B $28.68B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTBSXRMD
P/E 40.0x 18.3x 21.5x
P/FCF 27.8x 19.3x 20.9x
P/Operating cash flow 21.2x 15.2x 19.0x
P/S 3.9x 3.1x 5.9x
P/B 3.6x 2.5x 5.7x
P/Tangible book 5.9x 3.4x 6.1x
EV/EBITDA 20.3x 14.1x 15.8x
EV/EBIT 32.3x 19.2x 17.5x
EV/Revenue 4.5x 3.6x 5.8x
EV/FCF 31.8x 22.7x 20.6x
EV/Operating cash flow 24.3x 17.9x 18.7x
PEG (3Y EPS CAGR) -13.92 0.42 0.99

Growth

14 metrics
MetricABTBSXRMD
Revenue growth (1Y) 10.0% 8.9% 9.0%
Revenue CAGR (3Y) 6.5% 15.3% 9.4%
Gross profit growth (1Y) 12.1% 9.8% 11.0%
Gross profit CAGR (3Y) 7.8% 15.1% 13.2%
Operating income growth (1Y) -13.8% 13.5% 8.5%
Operating income CAGR (3Y) 3.5% 22.1% 18.2%
Net income growth (1Y) -66.4% 25.5% 10.8%
Net income CAGR (3Y) -3.1% 41.7% 20.7%
EPS growth (1Y) -66.1% 29.2% 13.5%
EPS CAGR (3Y) -2.9% 44.0% 21.8%
Operating cash flow growth (1Y) -2.9% -8.5% -6.0%
Operating cash flow CAGR (3Y) 10.6% 21.6% 23.7%
Free cash flow growth (1Y) -2.3% -12.9% -9.0%
Free cash flow CAGR (3Y) 14.6% 25.2% 25.5%

Profitability

14 metrics
MetricABTBSXRMD
Gross margin 56.9% 69.1% 61.1%
EBITDA margin 21.9% 25.5% 36.4%
Operating margin 13.8% 18.7% 33.0%
Pretax margin 13.6% 17.3% 35.1%
Net margin 9.7% 16.6% 27.8%
FCF margin 14.0% 15.8% 28.1%
Operating cash flow margin 18.4% 20.1% 30.9%
Return on equity 9.1% 13.7% 25.4%
Return on assets 4.3% 7.7% 18.5%
Return on invested capital 5.7% 9.9% 22.0%
Return on capital employed 7.2% 10.0% 26.1%
Asset turnover 0.4x 0.5x 0.7x
Cash conversion (OCF / net income) 1.9x 1.2x 1.1x
Stock comp / revenue 1.5% 1.5% 2.0%

Financial Health

11 metrics
MetricABTBSXRMD
Debt / assets 28.8% 26.3% 5.0%
Debt / equity 0.6x 0.5x 0.1x
Net debt / EBITDA 2.5x 2.1x -0.3x
Debt / FCF 4.6x 3.6x 0.3x
Liabilities / assets 52.3% 43.1% 27.6%
Equity / assets 47.7% 56.9% 72.4%
Interest coverage 6.7x 10.5x 81.1x
Current ratio 1.5x 1.4x 2.6x
Quick ratio 0.8x 0.6x 1.5x
Cash ratio 0.3x 0.1x 0.8x
Altman Z-score 3.36 3.03 12.00

Shareholder Returns

7 metrics
MetricABTBSXRMD
Dividend yield 2.3% – 1.1%
Net buyback yield 0.7% -0.3% 4.2%
Shareholder yield 3.0% -0.3% 5.3%
Payout ratio (earnings) 92.0% – –
Payout ratio (FCF) 64.0% – –
Dividend growth (1Y) 6.9% – –
Dividend CAGR (3Y) 7.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTBSXRMD
Forward P/E 19.1xFY2026 14.5xFY2026 18.5xFY2027
EPS, next fiscal year $5.69FY2026 $3.06FY2026 $12.92FY2027
EPS growth, next FY +10.5%FY2026 0.0%FY2026 +15.7%FY2027
EPS growth, the year after +10.2% +8.2% +8.9%
Revenue, next fiscal year $52.99BFY2026 $20.48BFY2026 $5.99BFY2027
Revenue growth, next FY +19.5%FY2026 +2.1%FY2026 +6.0%FY2027
Revenue growth, the year after -2.3% -4.0% -3.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTBSXRMD
Held by institutions 79.2% 90.5% 68.7%
Institutions holding 2,983 1,484 889
Change in shares held, QoQ +0.3% -0.7% +3.2%
Institutions buying 1,261 738 404
Institutions selling 1,379 612 360
Buyers to sellers 0.91 1.21 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTBSXRMD
ABT 1.00 0.40 0.41
BSX 0.40 1.00 0.24
RMD 0.41 0.24 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, BSX and RMD?

Abbott Laboratories (ABT) is the largest by market capitalisation: Abbott Laboratories (ABT) $187.09B, Boston Scientific (BSX) $63.31B, Resmed (RMD) $34.24B.

Which stock is cheaper, ABT, BSX and RMD?

Boston Scientific (BSX) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 39.8x, Boston Scientific (BSX) 18.1x, Resmed (RMD) 21.5x). On next year's consensus earnings, Boston Scientific (BSX) is cheapest (Abbott Laboratories (ABT) 19.1x, Boston Scientific (BSX) 14.5x, Resmed (RMD) 18.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Boston Scientific (BSX) +8.9%, Resmed (RMD) +9.0%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Boston Scientific (BSX) 16.6%, Resmed (RMD) 27.8%). On return on invested capital, Resmed (RMD) leads (Abbott Laboratories (ABT) 5.7%, Boston Scientific (BSX) 9.9%, Resmed (RMD) 22.0%).

Which stock has performed better?

Over the past year Resmed (RMD) returned the most: Abbott Laboratories (ABT) -16.0%, Boston Scientific (BSX) -57.8%, Resmed (RMD) -5.0%. Over five years, Boston Scientific (BSX) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Boston Scientific (BSX) +1.1%/yr, Resmed (RMD) -1.2%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Abbott Laboratories (ABT) 0.02%, Boston Scientific (BSX) 0.00%, Resmed (RMD) 0.00%. Boston Scientific (BSX) and Resmed (RMD) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Boston Scientific (BSX) 41.5%, Resmed (RMD) 31.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, BSX and RMD?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Resmed (RMD) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.